As a result, for stroke prevention in T2DM patients, besides injection therapy with glucagon-like peptide-1 receptor agonists (GLP-1 RAs), which have been shown to reduce the risk of stroke in some clinical trials (10), another oral glucose-lowering agent should be considered in daily practice because some patients may not accept or tolerate injection therapy. The gene discussed is GLP1R; the disease is Stroke.